Egle Therapeutics develops first-in-class immunotherapies that target regulatory T cells (Tregs) using proprietary IL-2 variants to modulate immune responses in oncology and autoimmune diseases. The company's approach addresses the challenge of immune suppression by selectively disarming tumor-infiltrating Tregs, enabling more effective treatment options for patients.
Funding
$46.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFounders
Product
Problem
Current cancer immunotherapies face challenges in effectively targeting and modulating regulatory T cells (Tregs) within the tumor microenvironment, which suppress anti-tumor immune responses. Existing approaches often lack the specificity needed to selectively disarm Tregs without affecting other immune cells, leading to potential systemic immune-related adverse events and limited efficacy.
Solution
Egle Therapeutics is developing first-in-class immunotherapies designed to selectively target and modulate Tregs, key drivers of immune suppression in oncology and autoimmune diseases. The company's approach utilizes proprietary, computationally designed IL-2 variants and antibody-specific targeting to either arm or disarm Tregs, restoring the immune response within the tumor microenvironment. Egle's technology platforms enable the creation of novel immunotherapies that specifically address the immunosuppressive functions of Tregs, offering the potential for more effective and targeted cancer treatments. Their lead candidate, EGL-001, is a Treg-selective anti-CTLA4-IL-2m fusion protein for oncology, while EGL-003 is a non-targeted IL-2 Treg engager for autoimmune diseases.
Target Audience
Egle Therapeutics' primary target audience includes patients with cancer and autoimmune diseases, as well as pharmaceutical companies seeking innovative immunotherapies to enhance their pipelines.
Features
- Computationally designed IL-2 modified variants for selective Treg targeting
- Antibody-specific targeting to arm or disarm immunosuppressive Tregs
- First-in-class technology platforms for building a pipeline of novel immunotherapies
- EGL-001: Treg-selective anti-CTLA4-IL-2m fusion protein for oncology
- EGL-003: Non-targeted IL-2 Treg engager for autoimmune diseases
- Target discovery platform unveiling novel therapeutic Treg targets